UY39208A - Vacuna recombinante contra covid-19 en vector viral de paramixovirus - Google Patents
Vacuna recombinante contra covid-19 en vector viral de paramixovirusInfo
- Publication number
- UY39208A UY39208A UY0001039208A UY39208A UY39208A UY 39208 A UY39208 A UY 39208A UY 0001039208 A UY0001039208 A UY 0001039208A UY 39208 A UY39208 A UY 39208A UY 39208 A UY39208 A UY 39208A
- Authority
- UY
- Uruguay
- Prior art keywords
- viral vector
- vaccine against
- recombinant vaccine
- against covid
- paramyxovirus viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18161—Methods of inactivation or attenuation
- C12N2760/18162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe una vacuna recombinante, activa o inactivada, contra COVID-19 que comprende un vector viral de la enfermedad de Newcastle y un vehículo, adyuvante y/o excipiente farmacéuticamente aceptable, caracterizada porque el vector viral es un virus capaz de generar una respuesta inmune celular y tiene insertada una secuencia de nucleótidos exógena de SARS-CoV-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2020/054545 WO2021229270A1 (es) | 2020-05-13 | 2020-05-13 | Vacuna recombinante contra covid-19 en vector viral |
PCT/IB2021/051491 WO2021229311A1 (es) | 2020-05-13 | 2021-02-22 | Vacuna recombinante contra covid-19 en vector viral de paramixovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39208A true UY39208A (es) | 2021-12-31 |
Family
ID=78525379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039208A UY39208A (es) | 2020-05-13 | 2021-05-11 | Vacuna recombinante contra covid-19 en vector viral de paramixovirus |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230226171A1 (es) |
EP (1) | EP4151232A1 (es) |
JP (1) | JP2023526309A (es) |
KR (1) | KR20230010663A (es) |
CN (1) | CN116710563A (es) |
AR (1) | AR122062A1 (es) |
AU (1) | AU2021269903A1 (es) |
BR (1) | BR112022023096A2 (es) |
CA (1) | CA3178542A1 (es) |
CO (1) | CO2022017623A2 (es) |
IL (1) | IL298080A (es) |
MX (1) | MX2022014250A (es) |
PE (1) | PE20230766A1 (es) |
UY (1) | UY39208A (es) |
WO (2) | WO2021229270A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20210318A1 (es) * | 2021-01-08 | 2021-02-16 | Farm Veterinarios S A C | Composicion inmunogenica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030224017A1 (en) | 2002-03-06 | 2003-12-04 | Samal Siba K. | Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors |
EA016217B1 (ru) | 2005-12-02 | 2012-03-30 | Маунт Синай Скул Оф Медсин | Химерные вирусы, представляющие неприродные поверхностные белки, и их применение |
EP2501404A1 (en) | 2009-11-16 | 2012-09-26 | Stichting Dienst Landbouwkundig Onderzoek | Use of newcastle disease virus-based vector for inducing an immune response in mammals |
JOP20190256A1 (ar) * | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
US10689716B1 (en) * | 2020-03-19 | 2020-06-23 | University Of Miami | Materials and methods for detecting coronavirus |
CN112011521A (zh) * | 2020-06-15 | 2020-12-01 | 浙江迪福润丝生物科技有限公司 | 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用 |
-
2020
- 2020-05-13 WO PCT/IB2020/054545 patent/WO2021229270A1/es active Application Filing
-
2021
- 2021-02-22 PE PE2022002638A patent/PE20230766A1/es unknown
- 2021-02-22 KR KR1020227041799A patent/KR20230010663A/ko unknown
- 2021-02-22 IL IL298080A patent/IL298080A/en unknown
- 2021-02-22 EP EP21804807.2A patent/EP4151232A1/en active Pending
- 2021-02-22 CN CN202180060963.9A patent/CN116710563A/zh active Pending
- 2021-02-22 JP JP2022569263A patent/JP2023526309A/ja active Pending
- 2021-02-22 BR BR112022023096A patent/BR112022023096A2/pt not_active Application Discontinuation
- 2021-02-22 US US17/998,737 patent/US20230226171A1/en active Pending
- 2021-02-22 CA CA3178542A patent/CA3178542A1/en active Pending
- 2021-02-22 WO PCT/IB2021/051491 patent/WO2021229311A1/es active Application Filing
- 2021-02-22 MX MX2022014250A patent/MX2022014250A/es unknown
- 2021-02-22 AU AU2021269903A patent/AU2021269903A1/en active Pending
- 2021-05-11 UY UY0001039208A patent/UY39208A/es unknown
- 2021-05-11 AR ARP210101290A patent/AR122062A1/es unknown
-
2022
- 2022-12-06 CO CONC2022/0017623A patent/CO2022017623A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021229311A1 (es) | 2021-11-18 |
WO2021229270A1 (es) | 2021-11-18 |
EP4151232A1 (en) | 2023-03-22 |
BR112022023096A2 (pt) | 2022-12-20 |
IL298080A (en) | 2023-01-01 |
CN116710563A (zh) | 2023-09-05 |
AU2021269903A1 (en) | 2022-12-15 |
US20230226171A1 (en) | 2023-07-20 |
JP2023526309A (ja) | 2023-06-21 |
MX2022014250A (es) | 2022-12-07 |
AR122062A1 (es) | 2022-08-10 |
CO2022017623A2 (es) | 2022-12-20 |
PE20230766A1 (es) | 2023-05-09 |
KR20230010663A (ko) | 2023-01-19 |
CA3178542A1 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022017623A2 (es) | Vacuna recombinante contra covid-19 en vector viral de paramixovirus | |
ES2150416T3 (es) | Vacuna virica defectiva producida por una linea celular complementada en trans. | |
CY1112749T1 (el) | Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας | |
BRPI0719469C1 (pt) | vetores de expressão derivados de retrovírus e métodos para produzir um vírus infeccioso de sarampo | |
NO20050396L (no) | Adjuvant viral partikkel | |
BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
PE20221111A1 (es) | Vacunas para vhb y metodos de tratamiento de vhb | |
PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
CL2022003150A1 (es) | Vacuna recombinante contra covid-19 en vector viral de paramixovirus | |
WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
WO2023042181A9 (en) | Recombinant vaccine against covid-19 to produce cellular response in individuals with pre-existing immunity | |
MX2023000884A (es) | Vacuna que usa vectores de influenza deficientes en m2/bm2. | |
JP2018501258A5 (es) | ||
CL2019000405A1 (es) | Vacunas virales. | |
BR112022003474A2 (pt) | Vacinas do vírus da hepatite b | |
CO2023004596A2 (es) | Vacuna heteróloga de estímulo primario | |
UY39400A (es) | Proteína estructural viral modificada | |
WO2022191801A3 (en) | Integrase defective hiv-based lentivirus mediated new generation covid-19 vaccine encoding sars-cov-2 spike protein | |
DOP2014000215A (es) | Virus de la enfermedad de marek modificado y vacunas elaboradas con él | |
CU20210063A7 (es) | Antígeno recombinante para la inducción de respuesta inmune contra el virus zika | |
BR112013028605A2 (pt) | vetor viral, vacina recombinante contra prrs e uso de uma vacina | |
Rosenthal et al. | Why don’t we have a vaccine against……….? Part 1. Viruses | |
Charles | Vaccines against Covid-19, Different Strategies towards the same Goal: Medicinal Chemistry & Chemical Biology Highlights |